Ibrutinib – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 79 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Ibrutinib is an orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Ibrutinib is an orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B-cell receptor signaling,...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.

Ibrutinib is an orally bioavailable, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B-cell receptor signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. The expression of BTK in tumor cells is also associated with increased proliferation and survival.

Ibrutinib is an oral inhibitor of Bruton’s tyrosine kinase that is used in the therapy of refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. Ibrutinib has not been associated with serum enzyme elevations during therapy but has been linked to rare cases of clinically apparent acute liver injury and to the reactivation of hepatitis B.

Ibrutinib is a member of the class of acrylamides that is (3R)-3-[4-amino-3-(4-phenoxy phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine in which the piperidine nitrogen is replaced by an acryloyl group. A selective and covalent inhibitor of the enzyme Bruton’s tyrosine kinase, it is used for the treatment of B-cell malignancies. It has a role as an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor and an antineoplastic agent. It is a pyrazolopyrimidine, an aromatic amine, an aromatic ether, a member of acrylamides, an N-acylpiperidine, and a tertiary carboxamide.

Mechanism of Action

Ibrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in the active site of BTK (Cys481), leading to its inhibition. The inhibition of BTK plays a role in the B-cell receptor signaling and thus, the presence of ibrutinib prevents the phosphorylation of downstream substrates such as PLC-γ.

or

Ibrutinib is a novel oral tyrosine kinase inhibitor that irreversibly binds and inhibits tyrosine-protein kinase BTK (Bruton tyrosine kinase). BTK has been found to be important in the function of B-cell receptor signaling and therefore in the maintenance and expansion of various B-cell malignancies including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Targeting BTK with ibrutinib has been found to be an effective strategy in treating these malignancies. Phase I clinical testing in non-Hodgkin’s lymphomas and CLL showed that the drug was extremely well tolerated with no major dose-limiting toxicities and a 54% overall response rate. Subsequently, two-phase Ib/II studies were performed on patients with CLL, one in relapsed/refractory CLL and one in previously untreated elderly patients with CLL. Both of these studies continued to show good tolerability of the drug and an overall response rate of about 71% with an extended duration of response. Another phase II study using ibrutinib in relapsed/refractory MCL was conducted and also showed that it was well tolerated with an overall response rate of 68% and an extended duration of response. Due to these results, the U.S. Food and Drug Administration granted accelerated approval for ibrutinib in November 2013 for patients with MCL who had received at least one prior therapy and in February 2014 for patients with CLL who had received at least one prior therapy. This review will discuss the preclinical pharmacology, pharmacokinetics, and clinical efficacy to date of ibrutinib in the treatment of CLL and MCL

In vitro studies have shown induction of CLL cell apoptosis even in presence of prosurvival factors. It has also been reported inhibition of CLL cell survival and proliferation as well as an impairment in cell migration and a reduction in the secretion of chemokines such as CCL3 and CCL4. The latter effect has been shown to produce regression in xenograft mouse models. Clinical studies for relapsed/refractory CLL in phases I and II showed an approximate 71% of overall response rate.. In the case of relapsed/refractory mantle cell lymphoma, approximately 70% of the tested patients presented a partial or complete response.. In clinical trials for relapsed/refractory diffuse large B-cell lymphoma, a partial response was found in between 15-20% of the patients studied; while for patients with relapsed/refractory Waldenstrom’s macroglobulinemia, a partial response was observed in over 75% of the patients tested. Finally, for patients with relapsed/refractory follicular lymphoma, a partial to complete response was obtained in approximately 54% of the patients.

Indications

  • Ibrutinib acquired accelerated approval for the treatment of mantle cell lymphoma who have received at least one prior therapy. Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma that develops in the outer edge of a lymph node. MCL is usually diagnosed at late stages and it is easily spread into bone marrow, spleen, liver, and gastrointestinal tract. Ibrutinib is indicated for the treatment of chronic lymphocytic leukemia (CLL) who have at least one prior therapy. CLL is a type of cancer caused by an overproduction of lymphocytes in the bone marrow. Some of the symptoms include swollen lymph nodes and tiredness. Ibrutinib is indicated for the treatment of chronic lymphocytic leukemia (CLL) with 17p deletion. CLL with 17p is a type of leukemia in which a deletion in 17p disrupts the tumor suppressor p53 by deleting one allele of the TP53 gene. The remaining allele is mainly inactivated and thus, this type of leukemia is unresponsive to p53-dependent treatments. Ibrutinib is indicated for the treatment of patients with Waldenstrom’s Macroglobulinemia (WM). WM, also called lymphoplasmacytic lymphoma, is a type of non-Hodgkin lymphoma in which the cancer cells make large amounts of macroglobulin. Macroglobulin is a monoclonal protein that corresponds to the type of IgM antibodies and the unrestricted formation of this protein causes typical symptoms such as excessive bleeding and affects vision and the nervous system.
  • Ibrutinib is an antineoplastic agent used to treat chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom’s Macroglobulinemia.
  • IMBRUVICA as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
  • IMBRUVICA as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) (see section 5. 1).
  • IMBRUVICA as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.
  • IMBRUVICA as a single agent is indicated for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemoimmunotherapy. IMBRUVICA in combination with rituximab is indicated for the treatment of adult patients with WM.
  • Treatment of chronic Graft versus Host Disease (cGvHD)
  • Treatment of lymphoplasmacytic lymphoma
  • Treatment of mantle cell lymphoma
  • Treatment of mature B-cell neoplasms
  • Ibrutinib is an oral inhibitor of Bruton’s tyrosine kinase that is used in the therapy of refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma.
  • Ibrutinib is indicated for the treatment of mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Waldenström’s macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic graft versus host disease (cGVHD)

Contraindications

  • Severe myelosuppression including bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।" data-rx-term="neutrophil" data-rx-definition="Neutrophil is a white blood cell important for fighting bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।">neutrophil count, which may increase infection risk. সহজ বাংলা: নিউট্রোফিল কম থাকা, সংক্রমণের ঝুঁকি বাড়তে পারে।" data-rx-term="neutropenia" data-rx-definition="Neutropenia means low neutrophil count, which may increase infection risk. সহজ বাংলা: নিউট্রোফিল কম থাকা, সংক্রমণের ঝুঁকি বাড়তে পারে।">neutropenia, platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।" data-rx-term="thrombocytopenia" data-rx-definition="Thrombocytopenia means low platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।">thrombocytopenia, and anemia has been reported in patients who received ibrutinib. Monitor complete blood counts monthly. A dosage adjustment or therapy discontinuation may be necessary for patients who develop hematologic toxicity.
  • a bad infection
  • anemia
  • an increased risk of bleeding
  • decreased blood platelets
  • low levels of a type of white blood cell called neutrophils
  • high blood pressure
  • rapid ventricular heartbeat
  • atrial fibrillation
  • atrial flutter
  • chronic heart failure
  • a stroke
  • bleeding
  • liver problems
  • recent operation
  • pregnancy
  • a patient who is producing milk and breastfeeding
  • lung tissue problem
  • progressive multifocal leukoencephalopathy, a type of brain infection
  • Child-Pugh class A liver impairment
  • Child-Pugh class B liver impairment
    Child-Pugh class C liver impairment

Dosage

Strengths: 70 mg/mL; 140 mg; 70 mg; 280 mg; 420 mg; 560 mg

Lymphoma

  • 560 mg orally once a day
  • Therapy should be continued until the disease progresses or unacceptable toxicity.
  • For the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy
  • For the treatment of adult patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy

Chronic Lymphocytic Leukemia

  • 420 mg orally once a day
  • Therapy should be continued until disease progresses or unacceptable toxicity.
  • This drug can be administered as a single agent, in combination with rituximab or obinutuzumab, or in combination with bendamustine and rituximab.
  • When administering in combination with rituximab or obinutuzumab, consider administering this drug prior to rituximab or obinutuzumab when given on the same day.
  • For the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
  • For the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with 17p deletion

Non-Hodgkin’s Lymphoma

  • 420 mg orally once a day
  • Therapy for Waldenstrom’s Macroglobulinemia (WM) should be continued until disease progression or unacceptable toxicity.
  • When used for WM, this drug can be administered as a single agent or in combination with rituximab.
  • Therapy for cGVHD should be continued until disease progression, recurrence of an underlying malignancy, or unacceptable toxicity
  • For the treatment of adult patients with Waldenstrom’s macroglobulinemia (WM)
  • For the treatment of adult patients with chronic graft-versus-host disease (cGVHD) after the failure of one or more lines of systemic therapy

Graft Versus Host Disease

  • 420 mg orally once a day
  • Therapy for Waldenstrom’s Macroglobulinemia (WM) should be continued until disease progression or unacceptable toxicity.
  • When used for WM, this drug can be administered as a single agent or in combination with rituximab.
  • Therapy for cGVHD should be continued until disease progression, recurrence of an underlying malignancy, or unacceptable toxicity
  • For the treatment of adult patients with Waldenstrom’s macroglobulinemia (WM)
  • For the treatment of adult patients with chronic graft-versus-host disease (cGVHD) after the failure of one or more lines of systemic therapy

Renal Dose Adjustments

  • Mild or moderate renal impairment (CrCl 25 mL/min or greater): No adjustment is recommended.
  • Severe renal impairment (CrCl less than 25 mL/min): Data not available

Liver Dose Adjustments

  • Mild hepatic impairment (Child-Pugh A): 140 mg orally daily
  • Moderate hepatic impairment (Child-Pugh B): 70 mg orally daily
  • Severe hepatic impairment (Child-Pugh C): Not recommended.

Dose Adjustments

ADVERSE REACTIONS:

  • Interrupt therapy for any Grade 3 or greater nonhematologic toxicity, Grade 3 or greater neutropenia with infection or fever, or Grade 4 hematological toxicity. -When toxicity has resolved to Grade 1 or baseline, therapy may be reinitiated at the starting dose.
  • If toxicity reoccurs, reduce the dose by 140 mg per day.
  • A second reduction of the dose by 140 mg may be considered if needed.
  • If toxicity persists or recurs following 2 dose reductions, discontinue therapy.

DOSE MODIFICATION FOR MCL AND MZL AFTER RECOVERY (Starting Dose = 560 mg):

  • The first occurrence of toxicity: Restart at 560 mg daily
  • The second occurrence of toxicity: Restart at 420 mg daily
  • The third occurrence of toxicity: Restart at 280 mg daily
  • The fourth occurrence of toxicity: Discontinue therapy

DOSE MODIFICATION FOR CLL/SLL, WM, AND CGVHD AFTER RECOVERY (Starting Dose = 420 mg):

  • The first occurrence of toxicity: Restart at 420 mg daily
  • The second occurrence of toxicity: Restart at 280 mg daily
  • The third occurrence of toxicity: Restart at 140 mg daily
  • The fourth occurrence of toxicity: Discontinue therapy

CONCOMITANT USE WITH CYP450 3A4 INHIBITORS:
PATIENTS WITH B-CELL MALIGNANCIES:

  • Concomitant administration of moderate CYP450 3A inhibitor: Administer 280 mg orally once daily; modify dose as recommended
  • Voriconazole 200 mg orally twice daily or posaconazole suspension 100 mg orally once daily, 100 mg orally twice daily, or 200 mg orally twice daily: Administer 140 mg orally once daily; modify dose as recommended
  • Posaconazole suspension 200 mg orally 3 times daily or 400 mg orally 2 times daily or posaconazole 300 mg IV once daily or posaconazole delayed-release tablets 300 mg orally once daily: Administer 70 mg orally once daily
  • Other strong CYP450 3A inhibitors: Avoid concomitant use; if these inhibitors will be used short-term (such as anti-infectives for 7 days or less): Interrupt therapy

PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE:

  • Concomitant administration of moderate CYP450 3A Inhibitor: Administer usual dose (420 mg orally once a day); modify dose as recommended.
  • Concomitant administration of voriconazole 200 mg orally 2 times a day or posaconazole suspension 100 mg orally once daily, 100 mg orally twice daily, or 200 mg orally twice daily: Administer 280 mg orally once daily; modify dose as recommended.
  • Concomitant administration of posaconazole suspension 200 mg orally 3 times daily or 400 mg orally 2 times daily or posaconazole 300 mg IV once daily or posaconazole delayed-release tablets 300 mg orally once daily: Administer 140 mg orally once daily; interrupt dose as recommended
  • Other strong CYP450 3A inhibitors: Avoid concomitant use; if these inhibitors will be used short-term (such as anti-infectives for 7 days or less): Interrupt therapy
  • After discontinuation of a CYP450 3A inhibitor, resume the previous dose of this drug.
  • Administer this drug at approximately the same time each day.
  • Instruct patients to swallow capsules or tablets whole with water, and not to open, break, or chew the capsules. Do not cut, crush, or chew the tablets.
  • Instruct the patient that this drug must not be taken with grapefruit juice or Seville oranges.
  • Administer a missed dose as soon as possible on the same day with a return to the normal dosing schedule the following day; do not administer extra doses to make up for the missed dose.

Side Effects

The Most Common

  • diarrhea
  • nausea
  • constipation
  • vomiting
  • stomach pain
  • heartburn or indigestion
  • decreased appetite
  • excessive tiredness or weakness
  • muscle, bone, and joint pain
  • muscle spasms
  • swelling of the hands, feet, ankles, or lower legs
  • rash
  • itching
  • sores in the mouth and throat
  • anxiety
  • difficulty falling asleep or staying asleep
  • cough, runny or stuffed nose
  • blurred vision
  • dry or watery eyes
  • pink eye
  • swelling of the face, throat, tongue, lips, and eyes
  • difficulty swallowing or breathing
  • hives
  • unusual bruising or bleeding
  • pink, red, or dark brown urine
  • bloody or black, tarry stools
  • nose bleeding
  • bloody vomit; or vomiting blood or brown material that resembles coffee grounds
  • seizures
  • fast or irregular heartbeat
  • shortness of breath
  • chest discomfort
  • dizziness, lightheadedness or feeling faint
  • vision changes
  • headache (that lasts a long time)
  • fever, chills, cough, red, warm skin, or other signs of infection
  • confusion
  • changes in your speech
  • decreased urination
  • painful, frequent, or urgent urination

More common

  • Back pain
  • bladder pain
  • bloating or swelling of the face, arms, hands, lower legs, or feet
  • bloody or black, tarry stools
  • bloody or cloudy urine
  • blurred vision
  • body aches or pain
  • chest pain or tightness
  • chills
  • confusion
  • cough
  • decreased frequency or amount of urine
  • difficult, burning, or painful urination
  • dizziness or lightheadedness
  • drowsiness
  • dry mouth
  • fainting
  • fast or irregular heartbeat
  • fever
  • frequent urge to urinate
  • headache
  • hoarseness
  • increased thirst
  • irregular heartbeat
  • itching
  • loss of appetite
  • lower back or side pain
  • nausea
  • rapid weight gain
  • seizures
  • severe headache
  • severe stomach pain
  • sore throat
  • tingling of the hands or feet
  • trouble breathing
  • ulcers, sores, or white spots in the mouth
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • unusual weight gain or loss
  • vomiting
  • vomiting of blood or material that looks like coffee grounds
  • wrinkled skin

Rare

  • Persistent non-healing sore
  • pink skin growth
  • reddish skin patch or irritated area
  • shiny skin bump
  • white, yellow or waxy scar-like area on the skin
  • Blistering, peeling, or loosening of the skin
  • dark urine
  • diarrhea
  • dilated neck veins
  • difficulty swallowing
  • a general feeling of tiredness or weakness
  • hives, skin rash
  • joint pain, stiffness, or swelling
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals
  • light-colored stools
  • muscle pain
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • red skin lesions, often with a purple center
  • red, irritated eyes
  • yellow eyes or skin

Drug Interaction

Pregnancy and Lactation

AU TGA pregnancy category: D
US FDA pregnancy category: Not Assigned

Pregnancy

This drug is a kinase inhibitor and can cause fetal harm based on findings from animal studies. Administration to pregnant animals during organogenesis at exposures up to 2 to 20 times the recommended human dose caused embryofetal toxicity including structural abnormalities. This drug should not be used during pregnancy unless the benefit outweighs the risk to the fetus. Advise females of reproductive potential and male patients to use effective contraceptive measures during therapy and for 1 to 3 months after. Females taking hormonal contraception should add a barrier contraceptive method as it is currently unknown whether this drug reduces the effectiveness of hormonal contraceptives. Male patients should not donate sperm during therapy and for 1 to 3 months after. Verify the pregnancy status of females of reproductive potential prior to initiating therapy. The time following treatment with this drug when it is safe to become pregnant is unknown.

Lactation

No information is available on the clinical use of ibrutinib during breastfeeding. Because ibrutinib is more than 97% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during ibrutinib therapy and for 1 week after the last dose.

How should this medicine be used?

Ibrutinib comes as a capsule and a tablet to take by mouth. It is usually taken once daily. Take ibrutinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take ibrutinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the capsules whole with a glass of water; do not open, break, or chew them. Swallow the tablets whole with a glass of water; do not cut, crush or chew them.

If you are receiving an obinutuzumab (Gazyva) injection or rituximab (Rituxan) injection, your doctor may tell you to take your dose of ibrutinib before you receive your injection.

Your doctor may decrease your dose, or interrupt or discontinue your treatment. This depends on how well the medication works for you and the side effects you experience. Talk to your doctor about how you are feeling during your treatment. Continue to take ibrutinib even if you feel well. Do not stop taking ibrutinib without talking to your doctor. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.

How should I take ibrutinib tablets and capsules

  • Swallow ibrutinib capsules or tablets whole with a glass of water.
  • Do not open, break, or chew the capsules.
  • Do not cut, crush, or chew the tablets.

How should I take ibrutinib oral suspension

  • Follow the Instructions for Use that comes with your oral suspension for information about the correct way to give a dose to your child. If you have questions about how to give this medication, talk to your healthcare provider or call 1-877-877-3536.
    • Each oral suspension carton contains:
      • 1 bottle of the medication with pre-inserted bottle adapter. Do not remove the bottle adapter
      • 2 reusable 3 mL oral dosing syringes (called ‘syringe’ in this Instructions for Use) measuring in 0.1 mL increments.
      • Only use the syringes that come with your medication. Do not use the syringes for other patients or with other medicines.
      • If you cannot read the markings on the syringes, throw them away and call 1-877-877-3536 to get new ones.
    • Preparing and giving a dose of ibrutinib oral suspension
      • Step 1: Gather and check supplies
        • Check your child’s prescribed dose in milliliters (mLs). Find this mL marking on the syringe.
        • If the dose is more than the marking on the syringe, split the dose between syringes as prescribed.
        • Gather bottle and syringe(s).
        • Check the bottle and make sure that it is the correct medication and the printed on it and the expiration date (“EXP”) has not passed.
        • Do not use if the expiration date has passed or the carton seal has been tampered with
      • Step 2: Record or check discard date
        • When opening the bottle for the first time, record the date that is 60 days from the day the bottle is opened underneath the words “Discard Date. Use within 60 days of opening.
      • Step 3: Shake bottle before each use
      • Step 4: Remove cap from bottle
        • Press down and twist the cap counterclockwise to remove it from the bottle.
        • If there is fluid on top of the adapter you may wipe it with clean disposable tissue.
        • Do not remove the bottle adapter.
      • Step 5: Attach syringe to bottle
        • Make sure the syringe is clean and dry before use.
        • Push the plunger down all the way.
        • Gently insert tip of the syringe into the adapter.
        • Turn the assembled bottle and syringe upside down.
      • Step 6: Fill syringe
        • Slowly pull the syringe plunger down, past the number of mLs for your prescribed dose.
        • Check for air bubbles and proceed to Step 7 for instructions on how to remove air bubbles.
      • Step 7: Remove air bubbles and adjust to the prescribed dose (mL)
        • Hold the syringe and tap the sides to send bubbles to the tip.
        • With the syringe attached to the bottle, push the plunger up to remove the air bubbles from the top.
        • After the bubbles are removed, push the plunger up until the top of the colored plunger is even with the markings on the syringe for the dose.
        • Air bubbles must be removed to ensure the correct dose. Repeat steps 6 and 7 if any air bubbles remain.
      • Step 8: Remove syringe from bottle
        • Turn the assembled bottle upright.
        • Hold the middle of the syringe and carefully remove it from the bottle.
        • Place the bottle aside.
        • Do not touch the plunger of the syringe to avoid accidentally spilling the medicine before you are ready.
        • Note: If more than 1 syringe is needed to give the full dose, repeat steps 5 to 8 with the second syringe to complete the prescribed dose.
      • Step 9: Give ibrutinib oral suspension
        • Place the tip of the syringe along the inside of your child’s cheek.
        • Slowly push the plunger all the way in to give the entire dose.
        • Repeat with second syringe if needed to complete the prescribed dose.
        • Note: this medication must be given as soon as possible after being drawn from the bottle.
        • Note: Make sure your child drinks water after swallowing the dose of medicine.
      • Step 10: Recap bottle
        • Place the cap back on the bottle.
        • Make sure the bottle is tightly closed between each use.
      • Step 11: Rinse syringe
        • Remove plunger from the syringe, rinse only with water and air dry.
        • Store the syringe in a clean, dry place.
        • Do not clean the syringe with soap or in the dishwasher.

What special precautions should I follow?

Before taking ibrutinib,

  • tell your doctor and pharmacist if you are allergic to ibrutinib, any other medications, or any of the ingredients in ibrutinib capsules or tablets. Ask your pharmacist for a list of the ingredients.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: anticoagulants (‘blood thinners’) such as warfarin (Coumadin, Jantoven); antifungals such as fluconazole (Diflucan), itraconazole (Onmel, Sporanox), ketoconazole (Nizoral), posaconazole (Noxafil), and voriconazole (Vfend); antiplatelet medications such as clopidogrel (Plavix), prasugrel (Effient), ticagrelor (Brilinta), and ticlopidine; aprepitant (Emend); carbamazepine (Carbatrol, Epitol, Tegretol, Teril); clarithromycin (Biaxin, Prevpac), digoxin (Lanoxin); diltiazem (Cardizem, Cartia, Tiazac, others); erythromycin (E.E.S., Erythrocin, others), certain medications to treat human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) such as efavirenz (Sustiva, in Atripla), indinavir (Crixivan), nelfinavir (Viracept), ritonavir (Norvir, in Kaletra), and saquinavir (Invirase); methotrexate (Otrexup, Rasuvo, Trexall, Xatmep); nefazodone; phenytoin (Dilantin, Phenytek); rifampin (Rifadin, Rifamate, Rimactane, others); verapamil (Calan, Covera, in Tarka, others); and telithromycin (no longer available in the U.S.; Ketek). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
  • tell your doctor what herbal products you are taking, especially St. John’s Wort.
  • tell your doctor if you have an infection or recently had surgery. Also tell your doctor if you smoke or if you have or have ever had diabetes, an irregular heartbeat, hypertension (high blood pressure), high cholesterol, bleeding problems, or heart, kidney, or liver disease.
  • tell your doctor if you are pregnant, plan to become pregnant, are breast-feeding, or if you plan on fathering a child. You should not become pregnant while you are taking ibrutinib. If you are female, you will need to take a pregnancy test before you start treatment and should use birth control to prevent pregnancy during your treatment with ibrutinib and for 1 month after you stop taking the medication. If you are male, you and your female partner should use birth control during your treatment with ibrutinib and continue for 1 month after your final dose. If you or your partner become pregnant while taking ibrutinib, call your doctor immediately. Ibrutinib can cause fetal harm.
  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking ibrutinib. Your doctor may tell you to stop taking ibrutinib 3 to 7 days before the surgery or procedure.
Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

General physician, urologist, nephrologist, or gynecologist depending on symptoms.

What to tell the doctor

  • Write burning, frequency, fever, flank pain, blood in urine, pregnancy, diabetes, and previous UTI history.

Questions to ask

  • Is this UTI, stone, prostate problem, diabetes-related, or another cause?
  • Do I need urine culture before antibiotics?

Tests to discuss

  • Urine routine/microscopy
  • Urine culture for recurrent/severe infection or treatment failure
  • Blood sugar and kidney function when indicated
  • Ultrasound if stone/obstruction/recurrent symptoms

Avoid these mistakes

  • Avoid self-starting antibiotics; wrong antibiotic can cause resistance.
  • Seek urgent care for fever with flank pain, pregnancy, vomiting, confusion, or inability to pass urine.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Orthopedic / spine specialist, physical medicine doctor, or qualified clinician
Tests to discuss with doctor
  • Neurological examination for leg power, sensation, reflexes, and straight leg raise
  • X-ray only if injury, deformity, long-lasting pain, or doctor suspects bone problem
  • MRI discussion if severe nerve symptoms, weakness, bladder/bowel problem, or persistent symptoms
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Is physiotherapy, posture correction, or activity modification needed?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Ibrutinib – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Mechanism of Action Ibrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in the active site of BTK (Cys481), leading to its inhibition. The inhibition of BTK plays a role in the B-cell receptor signaling and thus, the presence of ibrutinib prevents the phosphorylation of downstream substrates such as PLC-γ. or Ibrutinib is a novel oral tyrosine kinase inhibitor that irreversibly binds and inhibits tyrosine-protein kinase BTK (Bruton tyrosine kinase). BTK has been found to be important in the function of B-cell receptor signaling and therefore in the maintenance and expansion of various B-cell malignancies including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Targeting BTK with ibrutinib has been found to be an effective strategy in treating these malignancies. Phase I clinical testing in non-Hodgkin's lymphomas and CLL showed that the drug was extremely well tolerated with no major dose-limiting toxicities and a 54% overall response rate. Subsequently, two-phase Ib/II studies were performed on patients with CLL, one in relapsed/refractory CLL and one in previously untreated elderly patients with CLL. Both of these studies continued to show good tolerability of the drug and an overall response rate of about 71% with an extended duration of response. Another phase II study using ibrutinib in relapsed/refractory MCL was conducted and also showed that it was well tolerated with an overall response rate of 68% and an extended duration of response. Due to these results, the U.S. Food and Drug Administration granted accelerated approval for ibrutinib in November 2013 for patients with MCL who had received at least one prior therapy and in February 2014 for patients with CLL who had received at least one prior therapy. This review will discuss the preclinical pharmacology, pharmacokinetics, and clinical efficacy to date of ibrutinib in the treatment of CLL and MCL In vitro studies have shown induction of CLL cell apoptosis even in presence of prosurvival factors. It has also been reported inhibition of CLL cell survival and proliferation as well as an impairment in cell migration and a reduction in the secretion of chemokines such as CCL3 and CCL4. The latter effect has been shown to produce regression in xenograft mouse models. Clinical studies for relapsed/refractory CLL in phases I and II showed an approximate 71% of overall response rate.. In the case of relapsed/refractory mantle cell lymphoma, approximately 70% of the tested patients presented a partial or complete response.. In clinical trials for relapsed/refractory diffuse large B-cell lymphoma, a partial response was found in between 15-20% of the patients studied; while for patients with relapsed/refractory Waldenstrom's macroglobulinemia, a partial response was observed in over 75% of the patients tested. Finally, for patients with relapsed/refractory follicular lymphoma, a partial to complete response was obtained in approximately 54% of the patients. Indications Ibrutinib acquired accelerated approval for the treatment of mantle cell lymphoma who have received at least one prior therapy. Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma that develops in the outer edge of a lymph node. MCL is usually diagnosed at late stages and it is easily spread into bone marrow, spleen, liver, and gastrointestinal tract. Ibrutinib is indicated for the treatment of chronic lymphocytic leukemia (CLL) who have at least one prior therapy. CLL is a type of cancer caused by an overproduction of lymphocytes in the bone marrow. Some of the symptoms include swollen lymph nodes and tiredness. Ibrutinib is indicated for the treatment of chronic lymphocytic leukemia (CLL) with 17p deletion. CLL with 17p is a type of leukemia in which a deletion in 17p disrupts the tumor suppressor p53 by deleting one allele of the TP53 gene. The remaining allele is mainly inactivated and thus, this type of leukemia is unresponsive to p53-dependent treatments. Ibrutinib is indicated for the treatment of patients with Waldenstrom's Macroglobulinemia (WM). WM, also called lymphoplasmacytic lymphoma, is a type of non-Hodgkin lymphoma in which the cancer cells make large amounts of macroglobulin. Macroglobulin is a monoclonal protein that corresponds to the type of IgM antibodies and the unrestricted formation of this protein causes typical symptoms such as excessive bleeding and affects vision and the nervous system. Ibrutinib is an antineoplastic agent used to treat chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's Macroglobulinemia. IMBRUVICA as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). IMBRUVICA as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) (see section 5. 1). IMBRUVICA as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy. IMBRUVICA as a single agent is indicated for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemoimmunotherapy. IMBRUVICA in combination with rituximab is indicated for the treatment of adult patients with WM. Treatment of chronic Graft versus Host Disease (cGvHD) Treatment of lymphoplasmacytic lymphoma Treatment of mantle cell lymphoma Treatment of mature B-cell neoplasms Ibrutinib is an oral inhibitor of Bruton’s tyrosine kinase that is used in the therapy of refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. Ibrutinib is indicated for the treatment of mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Waldenström's macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic graft versus host disease (cGVHD) Contraindications Severe myelosuppression including neutropenia, thrombocytopenia, and anemia has been reported in patients who received ibrutinib. Monitor complete blood counts monthly. A dosage adjustment or therapy discontinuation may be necessary for patients who develop hematologic toxicity. a bad infection anemia an increased risk of bleeding decreased blood platelets low levels of a type of white blood cell called neutrophils high blood pressure rapid ventricular heartbeat atrial fibrillation atrial flutter chronic heart failure a stroke bleeding liver problems recent operation pregnancy a patient who is producing milk and breastfeeding lung tissue problem progressive multifocal leukoencephalopathy, a type of brain infection Child-Pugh class A liver impairment Child-Pugh class B liver impairment Child-Pugh class C liver impairment Dosage Strengths: 70 mg/mL; 140 mg; 70 mg; 280 mg; 420 mg; 560 mg Lymphoma 560 mg orally once a day Therapy should be continued until the disease progresses or unacceptable toxicity. For the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy For the treatment of adult patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy Chronic Lymphocytic Leukemia 420 mg orally once a day Therapy should be continued until disease progresses or unacceptable toxicity. This drug can be administered as a single agent, in combination with rituximab or obinutuzumab, or in combination with bendamustine and rituximab. When administering in combination with rituximab or obinutuzumab, consider administering this drug prior to rituximab or obinutuzumab when given on the same day. For the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) For the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with 17p deletion Non-Hodgkin's Lymphoma 420 mg orally once a day Therapy for Waldenstrom's Macroglobulinemia (WM) should be continued until disease progression or unacceptable toxicity. When used for WM, this drug can be administered as a single agent or in combination with rituximab. Therapy for cGVHD should be continued until disease progression, recurrence of an underlying malignancy, or unacceptable toxicity For the treatment of adult patients with Waldenstrom's macroglobulinemia (WM) For the treatment of adult patients with chronic graft-versus-host disease (cGVHD) after the failure of one or more lines of systemic therapy Graft Versus Host Disease 420 mg orally once a day Therapy for Waldenstrom's Macroglobulinemia (WM) should be continued until disease progression or unacceptable toxicity. When used for WM, this drug can be administered as a single agent or in combination with rituximab. Therapy for cGVHD should be continued until disease progression, recurrence of an underlying malignancy, or unacceptable toxicity For the treatment of adult patients with Waldenstrom's macroglobulinemia (WM) For the treatment of adult patients with chronic graft-versus-host disease (cGVHD) after the failure of one or more lines of systemic therapy Renal Dose Adjustments Mild or moderate renal impairment (CrCl 25 mL/min or greater): No adjustment is recommended. Severe renal impairment (CrCl less than 25 mL/min): Data not available Liver Dose Adjustments Mild hepatic impairment (Child-Pugh A): 140 mg orally daily Moderate hepatic impairment (Child-Pugh B): 70 mg orally daily Severe hepatic impairment (Child-Pugh C): Not recommended. Dose Adjustments ADVERSE REACTIONS: Interrupt therapy for any Grade 3 or greater nonhematologic toxicity, Grade 3 or greater neutropenia with infection or fever, or Grade 4 hematological toxicity. -When toxicity has resolved to Grade 1 or baseline, therapy may be reinitiated at the starting dose. If toxicity reoccurs, reduce the dose by 140 mg per day. A second reduction of the dose by 140 mg may be considered if needed. If toxicity persists or recurs following 2 dose reductions, discontinue therapy. DOSE MODIFICATION FOR MCL AND MZL AFTER RECOVERY (Starting Dose = 560 mg): The first occurrence of toxicity: Restart at 560 mg daily The second occurrence of toxicity: Restart at 420 mg daily The third occurrence of toxicity: Restart at 280 mg daily The fourth occurrence of toxicity: Discontinue therapy DOSE MODIFICATION FOR CLL/SLL, WM, AND CGVHD AFTER RECOVERY (Starting Dose = 420 mg): The first occurrence of toxicity: Restart at 420 mg daily The second occurrence of toxicity: Restart at 280 mg daily The third occurrence of toxicity: Restart at 140 mg daily The fourth occurrence of toxicity: Discontinue therapy CONCOMITANT USE WITH CYP450 3A4 INHIBITORS: PATIENTS WITH B-CELL MALIGNANCIES: Concomitant administration of moderate CYP450 3A inhibitor: Administer 280 mg orally once daily; modify dose as recommended Voriconazole 200 mg orally twice daily or posaconazole suspension 100 mg orally once daily, 100 mg orally twice daily, or 200 mg orally twice daily: Administer 140 mg orally once daily; modify dose as recommended Posaconazole suspension 200 mg orally 3 times daily or 400 mg orally 2 times daily or posaconazole 300 mg IV once daily or posaconazole delayed-release tablets 300 mg orally once daily: Administer 70 mg orally once daily Other strong CYP450 3A inhibitors: Avoid concomitant use; if these inhibitors will be used short-term (such as anti-infectives for 7 days or less): Interrupt therapy PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE: Concomitant administration of moderate CYP450 3A Inhibitor: Administer usual dose (420 mg orally once a day); modify dose as recommended. Concomitant administration of voriconazole 200 mg orally 2 times a day or posaconazole suspension 100 mg orally once daily, 100 mg orally twice daily, or 200 mg orally twice daily: Administer 280 mg orally once daily; modify dose as recommended. Concomitant administration of posaconazole suspension 200 mg orally 3 times daily or 400 mg orally 2 times daily or posaconazole 300 mg IV once daily or posaconazole delayed-release tablets 300 mg orally once daily: Administer 140 mg orally once daily; interrupt dose as recommended Other strong CYP450 3A inhibitors: Avoid concomitant use; if these inhibitors will be used short-term (such as anti-infectives for 7 days or less): Interrupt therapy After discontinuation of a CYP450 3A inhibitor, resume the previous dose of this drug. Administer this drug at approximately the same time each day. Instruct patients to swallow capsules or tablets whole with water, and not to open, break, or chew the capsules. Do not cut, crush, or chew the tablets. Instruct the patient that this drug must not be taken with grapefruit juice or Seville oranges. Administer a missed dose as soon as possible on the same day with a return to the normal dosing schedule the following day; do not administer extra doses to make up for the missed dose. Side Effects The Most Common diarrhea nausea constipation vomiting stomach pain heartburn or indigestion decreased appetite excessive tiredness or weakness muscle, bone, and joint pain muscle spasms swelling of the hands, feet, ankles, or lower legs rash itching sores in the mouth and throat anxiety difficulty falling asleep or staying asleep cough, runny or stuffed nose blurred vision dry or watery eyes pink eye swelling of the face, throat, tongue, lips, and eyes difficulty swallowing or breathing hives unusual bruising or bleeding pink, red, or dark brown urine bloody or black, tarry stools nose bleeding bloody vomit; or vomiting blood or brown material that resembles coffee grounds seizures fast or irregular heartbeat shortness of breath chest discomfort dizziness, lightheadedness or feeling faint vision changes headache (that lasts a long time) fever, chills, cough, red, warm skin, or other signs of infection confusion changes in your speech decreased urination painful, frequent, or urgent urination More common Back pain bladder pain bloating or swelling of the face, arms, hands, lower legs, or feet bloody or black, tarry stools bloody or cloudy urine blurred vision body aches or pain chest pain or tightness chills confusion cough decreased frequency or amount of urine difficult, burning, or painful urination dizziness or lightheadedness drowsiness dry mouth fainting fast or irregular heartbeat fever frequent urge to urinate headache hoarseness increased thirst irregular heartbeat itching loss of appetite lower back or side pain nausea rapid weight gain seizures severe headache severe stomach pain sore throat tingling of the hands or feet trouble breathing ulcers, sores, or white spots in the mouth unusual bleeding or bruising unusual tiredness or weakness unusual weight gain or loss vomiting vomiting of blood or material that looks like coffee grounds wrinkled skin Rare Persistent non-healing sore pink skin growth reddish skin patch or irritated area shiny skin bump white, yellow or waxy scar-like area on the skin Blistering, peeling, or loosening of the skin dark urine diarrhea dilated neck veins difficulty swallowing a general feeling of tiredness or weakness hives, skin rash joint pain, stiffness, or swelling large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals light-colored stools muscle pain puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue red skin lesions, often with a purple center red, irritated eyes yellow eyes or skin Drug Interaction DRUG INTERACTION Abaloparatide The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Ibrutinib. Abametapir The serum concentration of Ibrutinib can be increased when it is combined with Abametapir. Abatacept The metabolism of Ibrutinib can be increased when combined with Abatacept. Abciximab The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Abciximab. Abiraterone The metabolism of Ibrutinib can be decreased when combined with Abiraterone. Acalabrutinib The metabolism of Ibrutinib can be decreased when combined with Acalabrutinib. Acebutolol The metabolism of Ibrutinib can be decreased when combined with Acebutolol. Acenocoumarol The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Acenocoumarol. Acetaminophen The metabolism of Ibrutinib can be decreased when combined with Acetaminophen. Acetazolamide The metabolism of Ibrutinib can be decreased when combined with Acetazolamide. Acetylsalicylic acid The risk or severity of adverse effects can be increased when Ibrutinib is combined with Acetylsalicylic acid. Adalimumab The metabolism of Ibrutinib can be increased when combined with Adalimumab. Adenovirus The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Ibrutinib. Aldesleukin The metabolism of Ibrutinib can be decreased when combined with Aldesleukin. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Ibrutinib. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ibrutinib. Alfentanil The metabolism of Ibrutinib can be decreased when combined with Alfentanil. Allogeneic The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Ibrutinib. Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Ibrutinib. Almotriptan The metabolism of Ibrutinib can be decreased when combined with Almotriptan. Alogliptin The metabolism of Ibrutinib can be decreased when combined with Alogliptin. Alpelisib The metabolism of Ibrutinib can be decreased when combined with Alpelisib. alpha-Linolenic alpha-Linolenic acid may increase the antiplatelet activities of Ibrutinib. Alprazolam The metabolism of Ibrutinib can be decreased when combined with Alprazolam. Alteplase The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Alteplase. Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Ibrutinib. Ambrisentan The metabolism of Ibrutinib can be decreased when combined with Ambrisentan. Aminophenazone The metabolism of Ibrutinib can be decreased when combined with Aminophenazone. Amiodarone The metabolism of Ibrutinib can be decreased when combined with Amiodarone. Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Ibrutinib. Amoxapine The metabolism of Amoxapine can be decreased when combined with Ibrutinib. Amphetamine The metabolism of Ibrutinib can be decreased when combined with Amphetamine. Amprenavir The metabolism of Ibrutinib can be decreased when combined with Amprenavir. Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Ibrutinib. Anagrelide The risk or severity of adverse effects can be increased when Ibrutinib is combined with Anagrelide. Anakinra The metabolism of Ibrutinib can be increased when combined with Anakinra. Ancrod The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Ancrod. Anifrolumab The risk or severity of adverse effects can be increased when Ibrutinib is combined with Anifrolumab. Anistreplase The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Anistreplase. Anthrax immune The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ibrutinib. Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Ibrutinib. Antilymphocyte The risk or severity of adverse effects can be increased when Ibrutinib is combined with Antilymphocyte immunoglobulin (horse). Antipyrine The metabolism of Ibrutinib can be decreased when combined with Antipyrine. Antithrombin Alfa The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Antithrombin Alfa. Antithrombin III The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Antithrombin III human. Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ibrutinib. Apalutamide The metabolism of Ibrutinib can be increased when combined with Apalutamide. Apixaban The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Apixaban. Apomorphine The metabolism of Ibrutinib can be decreased when combined with Apomorphine. Apremilast The metabolism of Ibrutinib can be increased when combined with Apremilast. Aprepitant The metabolism of Ibrutinib can be decreased when combined with Aprepitant. Ardeparin The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Ardeparin. Arformoterol The metabolism of Ibrutinib can be decreased when combined with Arformoterol. Argatroban The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Argatroban. Aripiprazole The metabolism of Ibrutinib can be decreased when combined with Aripiprazole. Aripiprazole The metabolism of Aripiprazole lauroxil can be decreased when combined with Ibrutinib. Armodafinil The metabolism of Ibrutinib can be increased when combined with Armodafinil. Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ibrutinib. Artemether The metabolism of Ibrutinib can be decreased when combined with Artemether. Artenimol The metabolism of Ibrutinib can be decreased when combined with Artenimol. Articaine The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Articaine. Astemizole The metabolism of Ibrutinib can be decreased when combined with Astemizole. ACOVID-19 Vaccine The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Ibrutinib. Asunaprevir The metabolism of Ibrutinib can be decreased when combined with Asunaprevir. Atazanavir The metabolism of Ibrutinib can be decreased when combined with Atazanavir. Atenolol The metabolism of Ibrutinib can be decreased when combined with Atenolol. Atomoxetine The metabolism of Ibrutinib can be decreased when combined with Atomoxetine. Atorvastatin The metabolism of Ibrutinib can be decreased when combined with Atorvastatin. Avanafil The serum concentration of Avanafil can be increased when it is combined with Ibrutinib. Axitinib The metabolism of Axitinib can be decreased when combined with Ibrutinib. Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Ibrutinib. Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Ibrutinib. Azelastine The metabolism of Ibrutinib can be decreased when combined with Azelastine. Bacillus The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Ibrutinib. Bacillus antigen The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Ibrutinib. Bacillus calmette The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Ibrutinib. Baricitinib The risk or severity of adverse effects can be increased when Ibrutinib is combined with Baricitinib. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Ibrutinib. BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Ibrutinib. Beclomethasone The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Ibrutinib. Belatacept The risk or severity of adverse effects can be increased when Belatacept is combined with Ibrutinib. Belimumab The risk or severity of adverse effects can be increased when Belimumab is combined with Ibrutinib. Belinostat The risk or severity of adverse effects can be increased when Belinostat is combined with Ibrutinib. Belumosudil The risk or severity of adverse effects can be increased when Ibrutinib is combined with Belumosudil. Bemiparin The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Bemiparin. Bendamustine The risk or severity of adverse effects can be increased when Bendamustine is combined with Ibrutinib. Bendroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Ibrutinib. Benzatropine The metabolism of Ibrutinib can be decreased when combined with Benzatropine. Benzocaine The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Benzocaine. Benzthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Ibrutinib. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Benzyl alcohol. Bepridil The metabolism of Ibrutinib can be decreased when combined with Bepridil. Berotralstat The metabolism of Ibrutinib can be decreased when combined with Berotralstat. Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Ibrutinib. Betamethasone The metabolism of Ibrutinib can be increased when combined with Betamethasone phosphate. Betaxolol The metabolism of Ibrutinib can be decreased when combined with Betaxolol. Betrixaban The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Betrixaban. Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Ibrutinib. Bicalutamide The metabolism of Ibrutinib can be decreased when combined with Bicalutamide. Bifonazole The metabolism of Ibrutinib can be decreased when combined with Bifonazole. Bimekizumab The metabolism of Ibrutinib can be increased when combined with Bimekizumab. Biperiden The metabolism of Ibrutinib can be decreased when combined with Biperiden. Bivalirudin The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Bivalirudin. Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Ibrutinib. Blinatumomab The risk or severity of adverse effects can be increased when Blinatumomab is combined with Ibrutinib. Boceprevir The metabolism of Ibrutinib can be decreased when combined with Boceprevir. Bordetella The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Ibrutinib. Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Ibrutinib. Bosutinib The metabolism of Ibrutinib can be decreased when combined with Bosutinib. Brentuximab The metabolism of Ibrutinib can be decreased when combined with Brentuximab vedotin. Brexpiprazole The metabolism of Brexpiprazole can be decreased when combined with Ibrutinib. Brodalumab The risk or severity of adverse effects can be increased when Ibrutinib is combined with Brodalumab. Bromocriptine The metabolism of Ibrutinib can be decreased when combined with Bromocriptine. Budesonide The risk or severity of adverse effects can be increased when Budesonide is combined with Ibrutinib. Bupivacaine The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Bupivacaine. Buprenorphine The metabolism of Ibrutinib can be decreased when combined with Buprenorphine. Bupropion The metabolism of Ibrutinib can be decreased when combined with Bupropion. Buspirone The metabolism of Ibrutinib can be decreased when combined with Buspirone. Busulfan The risk or severity of adverse effects can be increased when Busulfan is combined with Ibrutinib. Butacaine The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Butamben. Cabazitaxel The metabolism of Cabazitaxel can be decreased when combined with Ibrutinib. Cabergoline The metabolism of Ibrutinib can be decreased when combined with Cabergoline. Canakinumab The metabolism of Ibrutinib can be increased when combined with Canakinumab. Candicidin The metabolism of Ibrutinib can be decreased when combined with Candicidin. Cangrelor The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Cangrelor. Cannabidiol The metabolism of Ibrutinib can be decreased when combined with Cannabidiol. Capecitabine The risk or severity of adverse effects can be increased when Capecitabine is combined with Ibrutinib. Caplacizumab The risk or severity of adverse effects can be increased when Ibrutinib is combined with Caplacizumab. Capsaicin The metabolism of Ibrutinib can be decreased when combined with Capsaicin. Carbamazepine The metabolism of Carbamazepine can be decreased when combined with Ibrutinib. Carbimazole The therapeutic efficacy of Carbimazole can be decreased when used in combination with Ibrutinib. Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Ibrutinib. Carfilzomib The risk or severity of adverse effects can be increased when Carfilzomib is combined with Ibrutinib. Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Ibrutinib. Carvedilol The metabolism of Ibrutinib can be decreased when combined with Carvedilol. Celecoxib The metabolism of Ibrutinib can be decreased when combined with Celecoxib. Celiprolol The metabolism of Ibrutinib can be decreased when combined with Celiprolol. Cenobamate The metabolism of Ibrutinib can be decreased when combined with Cenobamate. Ceritinib The metabolism of Ibrutinib can be decreased when combined with Ceritinib. Cerivastatin The metabolism of Ibrutinib can be decreased when combined with Cerivastatin. Certolizumab The metabolism of Ibrutinib can be increased when combined with Certolizumab pegol. Cevimeline The metabolism of Ibrutinib can be decreased when combined with Cevimeline. Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Ibrutinib. Chloramphenicol The metabolism of Ibrutinib can be decreased when combined with Chloramphenicol. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Chloroprocaine. Chloroquine The metabolism of Ibrutinib can be decreased when combined with Chloroquine. Chlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Ibrutinib. Chlorpheniramine The metabolism of Ibrutinib can be decreased when combined with Chlorpheniramine. Chlorpromazine The metabolism of Ibrutinib can be decreased when combined with Chlorpromazine. Chlorzoxazone The metabolism of Ibrutinib can be decreased when combined with Chlorzoxazone. Cholecalciferol The metabolism of Ibrutinib can be decreased when combined with Cholecalciferol. Ciclesonide The risk or severity of adverse effects can be increased when Ciclesonide is combined with Ibrutinib. Cilostazol The risk or severity of adverse effects can be increased when Ibrutinib is combined with Cilostazol. Cimetidine The metabolism of Ibrutinib can be decreased when combined with Cimetidine. Cinacalcet The metabolism of Ibrutinib can be decreased when combined with Cinacalcet. Cinchocaine The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Cinchocaine. Cinnarizine The metabolism of Ibrutinib can be decreased when combined with Cinnarizine. Ciprofloxacin The metabolism of Ibrutinib can be decreased when combined with Ciprofloxacin. Cisapride The metabolism of Ibrutinib can be decreased when combined with Cisapride. Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Ibrutinib. Citalopram The metabolism of Ibrutinib can be decreased when combined with Citalopram. Cladribine The risk or severity of adverse effects can be increased when Cladribine is combined with Ibrutinib. Clarithromycin The metabolism of Ibrutinib can be decreased when combined with Clarithromycin. Clemastine The metabolism of Ibrutinib can be decreased when combined with Clemastine. Clevidipine The metabolism of Ibrutinib can be decreased when combined with Clevidipine. Clindamycin The metabolism of Ibrutinib can be decreased when combined with Clindamycin. Clobazam The metabolism of Ibrutinib can be decreased when combined with Clobazam. Clobetasol The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Ibrutinib. Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Ibrutinib. Clofazimine The metabolism of Ibrutinib can be decreased when combined with Clofazimine. Clomipramine The metabolism of Clomipramine can be decreased when combined with Ibrutinib. Clonidine The metabolism of Clonidine can be decreased when combined with Ibrutinib. Clopidogrel The risk or severity of adverse effects can be increased when Ibrutinib is combined with Clopidogrel. Clostridium The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ibrutinib. Clozapine The metabolism of Ibrutinib can be decreased when combined with Clozapine. Cobicistat The metabolism of Ibrutinib can be decreased when combined with Cobicistat. Cocaine The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Cocaine. Codeine The metabolism of Ibrutinib can be decreased when combined with Codeine. Colchicine The metabolism of Ibrutinib can be decreased when combined with Colchicine. Conivaptan The metabolism of Ibrutinib can be decreased when combined with Conivaptan. Copanlisib The metabolism of Copanlisib can be decreased when combined with Ibrutinib. Corticotropin The risk or severity of adverse effects can be increased when Corticotropin is combined with Ibrutinib. Cortisone acetate The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Ibrutinib. Corynebacterium The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ibrutinib. Crizotinib The metabolism of Ibrutinib can be decreased when combined with Crizotinib. Curcumin The metabolism of Ibrutinib can be decreased when combined with Curcumin. Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ibrutinib. Cyclopenthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Ibrutinib. Cyclophosphamide The metabolism of Cyclophosphamide can be decreased when combined with Ibrutinib. Cyclosporine Ibrutinib may increase the immunosuppressive activities of Cyclosporine. Cyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Ibrutinib. Cyproterone acetate The metabolism of Ibrutinib can be decreased when combined with Cyproterone acetate. Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Ibrutinib. Dabigatran The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Dabigatran. Dabigatran etexilate The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Dabigatran etexilate. Dabrafenib The metabolism of Ibrutinib can be decreased when combined with Dabrafenib. Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Ibrutinib. Daclatasvir The metabolism of Daclatasvir can be decreased when combined with Ibrutinib. Dacomitinib The metabolism of Dacomitinib can be decreased when combined with Ibrutinib. Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Ibrutinib. Dalfopristin The metabolism of Ibrutinib can be decreased when combined with Dalfopristin. Dalteparin The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Dalteparin. Danaparoid The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Danaparoid. Danazol The metabolism of Ibrutinib can be decreased when combined with Danazol. Dapagliflozin The metabolism of Ibrutinib can be decreased when combined with Dapagliflozin. Dapsone The metabolism of Ibrutinib can be decreased when combined with Dapsone. Darbepoetin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ibrutinib. Darifenacin The metabolism of Ibrutinib can be decreased when combined with Darifenacin. Darunavir The metabolism of Ibrutinib can be decreased when combined with Darunavir. Dasabuvir The metabolism of Dasabuvir can be decreased when combined with Ibrutinib. Dasatinib The metabolism of Ibrutinib can be decreased when combined with Dasatinib. Daunorubicin The metabolism of Ibrutinib can be decreased when combined with Daunorubicin. Debrisoquine The metabolism of Ibrutinib can be decreased when combined with Debrisoquine. Decitabine The risk or severity of adverse effects can be increased when Decitabine is combined with Ibrutinib. Defibrotide The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Defibrotide. Deflazacort The risk or severity of adverse effects can be increased when Ibrutinib is combined with Deflazacort. Delavirdine The metabolism of Ibrutinib can be decreased when combined with Delavirdine. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Ibrutinib. Desipramine The metabolism of Ibrutinib can be decreased when combined with Desipramine. Desirudin The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Desirudin. Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Ibrutinib. Desvenlafaxine The metabolism of Ibrutinib can be decreased when combined with Desvenlafaxine. Deucravacitinib The risk or severity of adverse effects can be increased when Ibrutinib is combined with Deucravacitinib. Deutetrabenazine The metabolism of Deutetrabenazine can be decreased when combined with Ibrutinib. Dexamethasone The metabolism of Ibrutinib can be decreased when combined with Dexamethasone. Dexamethasone The metabolism of Ibrutinib can be increased when combined with Dexamethasone acetate. Dexchlorphenira The metabolism of Ibrutinib can be decreased when combined with Dexchlorpheniramine maleate. Dexfenfluramine The metabolism of Ibrutinib can be decreased when combined with Dexfenfluramine. Dexmedetomidine The metabolism of Ibrutinib can be decreased when combined with Dexmedetomidine. Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ibrutinib. Dextran The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Dextran. Dextroamphetamine The metabolism of Ibrutinib can be decreased when combined with Dextroamphetamine. Dextromethorphan The metabolism of Ibrutinib can be decreased when combined with Dextromethorphan. Dextropropoxyphene The metabolism of Ibrutinib can be decreased when combined with Dextropropoxyphene. Diacerein The metabolism of Ibrutinib can be decreased when combined with Diacerein. Diazepam The metabolism of Ibrutinib can be decreased when combined with Diazepam. Dicoumarol The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Dicoumarol. Diethylstilbestrol The metabolism of Ibrutinib can be decreased when combined with Diethylstilbestrol. Difluocortolone The risk or severity of adverse effects can be increased when Ibrutinib is combined with Difluocortolone. Dihydrocodeine The metabolism of Ibrutinib can be decreased when combined with Dihydrocodeine. Dihydroergotamine The metabolism of Ibrutinib can be decreased when combined with Dihydroergotamine. Diltiazem The metabolism of Ibrutinib can be decreased when combined with Diltiazem. Dimethyl fumarate The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Ibrutinib. Dimethyl sulfoxide The metabolism of Ibrutinib can be decreased when combined with Dimethyl sulfoxide. Dinutuximab The risk or severity of adverse effects can be increased when Ibrutinib is combined with Dinutuximab. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Diphenhydramine. Dipyridamole The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Dipyridamole. Diroximel The risk or severity of adverse effects can be increased when Ibrutinib is combined with Diroximel fumarate. Disulfiram The metabolism of Ibrutinib can be decreased when combined with Disulfiram. Docetaxel The metabolism of Ibrutinib can be decreased when combined with Docetaxel. Doconexent Doconexent may increase the antiplatelet activities of Ibrutinib. Dolasetron The metabolism of Ibrutinib can be decreased when combined with Dolasetron. Domperidone The metabolism of Ibrutinib can be decreased when combined with Domperidone. Donepezil The metabolism of Ibrutinib can be decreased when combined with Donepezil. Doravirine The metabolism of Doravirine can be decreased when combined with Ibrutinib. Dosulepin The metabolism of Ibrutinib can be decreased when combined with Dosulepin. Doxazosin The metabolism of Ibrutinib can be decreased when combined with Doxazosin. Doxepin The metabolism of Ibrutinib can be decreased when combined with Doxepin. Doxorubicin The metabolism of Ibrutinib can be decreased when combined with Doxorubicin. Dronabinol The metabolism of Ibrutinib can be decreased when combined with Dronabinol. Dronedarone The metabolism of Ibrutinib can be decreased when combined with Dronedarone. Drotrecogin alfa The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Drotrecogin alfa. Duloxetine The metabolism of Ibrutinib can be decreased when combined with Duloxetine. Dutasteride The metabolism of Ibrutinib can be decreased when combined with Dutasteride. Dyclonine The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Dyclonine. Ebola Zaire The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Ibrutinib. Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Ibrutinib. Edetic acid The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Edetic acid. Edoxaban The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Edoxaban. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Ibrutinib. Efavirenz The metabolism of Ibrutinib can be decreased when combined with Efavirenz. Elagolix The metabolism of Elagolix can be decreased when combined with Ibrutinib. Elbasvir The metabolism of Ibrutinib can be decreased when combined with Elbasvir. Eletriptan The metabolism of Ibrutinib can be decreased when combined with Eletriptan. Elexacaftor The metabolism of Elexacaftor can be decreased when combined with Ibrutinib. Eliglustat The metabolism of Ibrutinib can be decreased when combined with Eliglustat. Elvitegravir The metabolism of Ibrutinib can be decreased when combined with Elvitegravir. Emapalumab The metabolism of Ibrutinib can be increased when combined with Emapalumab. Enasidenib The metabolism of Ibrutinib can be decreased when combined with Enasidenib. Encainide The metabolism of Ibrutinib can be decreased when combined with Encainide. Encorafenib The metabolism of Encorafenib can be decreased when combined with Ibrutinib. Enoxaparin The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Enoxaparin. Entacapone The metabolism of Ibrutinib can be decreased when combined with Entacapone. Enzalutamide The serum concentration of Ibrutinib can be decreased when it is combined with Enzalutamide. Epinastine The metabolism of Ibrutinib can be decreased when combined with Epinastine. Epinephrine The metabolism of Ibrutinib can be decreased when combined with Epinephrine. Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Ibrutinib. Eplerenone The metabolism of Ibrutinib can be decreased when combined with Eplerenone. Epoprostenol The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Epoprostenol. Eptifibatide The risk or severity of adverse effects can be increased when Ibrutinib is combined with Eptifibatide. Ergotamine The metabolism of Ibrutinib can be decreased when combined with Ergotamine. Eribulin The risk or severity of adverse effects can be increased when Eribulin is combined with Ibrutinib. Erlotinib The metabolism of Ibrutinib can be decreased when combined with Erlotinib. Erythromycin The metabolism of Ibrutinib can be decreased when combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ibrutinib. Escitalopram The serum concentration of Ibrutinib can be increased when it is combined with Escitalopram. Esmolol The metabolism of Ibrutinib can be decreased when combined with Esmolol. Estradiol The metabolism of Ibrutinib can be decreased when combined with Estradiol. Estradiol acetate The metabolism of Estradiol acetate can be decreased when combined with Ibrutinib. Estradiol benzoate The metabolism of Estradiol benzoate can be decreased when combined with Ibrutinib. Estradiol cypionate The metabolism of Estradiol cypionate can be decreased when combined with Ibrutinib. Estradiol dienanthate The metabolism of Estradiol dienanthate can be decreased when combined with Ibrutinib. Estradiol valerate The metabolism of Estradiol valerate can be decreased when combined with Ibrutinib. Estramustine The risk or severity of adverse effects can be increased when Estramustine is combined with Ibrutinib. Etanercept The metabolism of Ibrutinib can be increased when combined with Etanercept. Ethambutol The metabolism of Ibrutinib can be decreased when combined with Ethambutol. Ethanol The metabolism of Ibrutinib can be decreased when combined with Ethanol. Ethinylestradiol The metabolism of Ibrutinib can be decreased when combined with Ethinylestradiol. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Etidocaine. Etoposide The metabolism of Ibrutinib can be decreased when combined with Etoposide. Etoricoxib The metabolism of Ibrutinib can be decreased when combined with Etoricoxib. Everolimus The metabolism of Ibrutinib can be decreased when combined with Everolimus. Famtozinameran The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Ibrutinib. Fedratinib The metabolism of Ibrutinib can be decreased when combined with Fedratinib. Felodipine The metabolism of Ibrutinib can be decreased when combined with Felodipine. Fenfluramine The metabolism of Ibrutinib can be decreased when combined with Fenfluramine. Fesoterodine The metabolism of Ibrutinib can be decreased when combined with Fesoterodine. Fexinidazole The metabolism of Ibrutinib can be decreased when combined with Fexinidazole. Filgotinib The risk or severity of adverse effects can be increased when Ibrutinib is combined with Filgotinib. Finasteride The metabolism of Ibrutinib can be decreased when combined with Finasteride. Fingolimod Ibrutinib may increase the immunosuppressive activities of Fingolimod. Flecainide The metabolism of Flecainide can be decreased when combined with Ibrutinib. Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Ibrutinib. Fluconazole The metabolism of Ibrutinib can be decreased when combined with Fluconazole. Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Ibrutinib. Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Ibrutinib. Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Ibrutinib. Fluindione The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Fluindione. Flunarizine The metabolism of Ibrutinib can be decreased when combined with Flunarizine. Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Ibrutinib. Fluocinolone The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Ibrutinib. Fluocinonide The risk or severity of adverse effects can be increased when Fluocinonide is combined with Ibrutinib. Fluocortolone The risk or severity of adverse effects can be increased when Fluocortolone is combined with Ibrutinib. Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Ibrutinib. Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Ibrutinib. Fluoxetine The serum concentration of Ibrutinib can be increased when it is combined with Fluoxetine. Flupentixol The risk or severity of myelosuppression can be increased when Flupentixol is combined with Ibrutinib. Fluphenazine The metabolism of Ibrutinib can be decreased when combined with Fluphenazine. Fluprednisolone The risk or severity of adverse effects can be increased when Ibrutinib is combined with Fluprednisolone. Flutamide The metabolism of Ibrutinib can be decreased when combined with Flutamide. Fluticasone The metabolism of Ibrutinib can be decreased when combined with Fluticasone. Fluticasone The metabolism of Ibrutinib can be decreased when combined with Fluticasone furoate. Fluticasone The metabolism of Ibrutinib can be decreased when combined with Fluticasone propionate. Fluvastatin The metabolism of Ibrutinib can be decreased when combined with Fluvastatin. Fluvoxamine The metabolism of Ibrutinib can be decreased when combined with Fluvoxamine. Follitropin The therapeutic efficacy of Follitropin can be decreased when used in combination with Ibrutinib. Fondaparinux The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Fondaparinux. Formoterol The metabolism of Ibrutinib can be decreased when combined with Formoterol. Fosaprepitant The metabolism of Ibrutinib can be decreased when combined with Fosaprepitant. Fosnetupitant The metabolism of Ibrutinib can be decreased when combined with Fosnetupitant. Fosphenytoin The metabolism of Ibrutinib can be increased when combined with Fosphenytoin. Fostamatinib The metabolism of Ibrutinib can be decreased when combined with Fostamatinib. Fusidic acid The metabolism of Ibrutinib can be decreased when combined with Fusidic acid. Galantamine The metabolism of Ibrutinib can be decreased when combined with Galantamine. Gallium nitrate The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Ibrutinib. Gefitinib The metabolism of Ibrutinib can be decreased when combined with Gefitinib. Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Ibrutinib. Gemtuzumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibrutinib. Givosiran The serum concentration of Ibrutinib can be increased when it is combined with Givosiran. Glatiramer The risk or severity of adverse effects can be increased when Glatiramer is combined with Ibrutinib. Glyburide The metabolism of Ibrutinib can be decreased when combined with Glyburide. Glycerol The metabolism of Ibrutinib can be decreased when combined with Glycerol phenylbutyrate. Golimumab The metabolism of Ibrutinib can be increased when combined with Golimumab. Guselkumab The risk or severity of adverse effects can be increased when Ibrutinib is combined with Guselkumab. Haemophilus The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Ibrutinib. Halofantrine The metabolism of Ibrutinib can be decreased when combined with Halofantrine. Haloperidol The metabolism of Ibrutinib can be decreased when combined with Haloperidol. Heparin The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Heparin. Hepatitis A Vaccine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ibrutinib. Hepatitis B The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ibrutinib. Human adenovirus The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Ibrutinib. Hydralazine The metabolism of Ibrutinib can be decreased when combined with Hydralazine. Hydrochlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Ibrutinib. Hydrocortisone The metabolism of Ibrutinib can be decreased when combined with Hydrocortisone. Hydrocortisone a The risk or severity of adverse effects can be increased when Ibrutinib is combined with Hydrocortisone acetate. Hydrocortisone The risk or severity of adverse effects can be increased when Ibrutinib is combined with Hydrocortisone butyrate. Hydrocortisone The metabolism of Hydrocortisone cypionate can be decreased when combined with Ibrutinib. Hydrocortisone The metabolism of Hydrocortisone phosphate can be decreased when combined with Ibrutinib. Hydrocortisone e The risk or severity of adverse effects can be increased when Ibrutinib is combined with Hydrocortisone succinate. Hydroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Ibrutinib. Hydroxychloroquine The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Ibrutinib. Hydroxyprogester The metabolism of Ibrutinib can be decreased when combined with Hydroxyprogesterone caproate. Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Ibrutinib. Hydroxyzine The metabolism of Ibrutinib can be decreased when combined with Hydroxyzine. Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ibrutinib. Icosapent Icosapent may increase the antiplatelet activities of Ibrutinib. Icosapent ethyl Icosapent ethyl may increase the antiplatelet activities of Ibrutinib. Idarubicin The risk or severity of adverse effects can be increased when Idarubicin is combined with Ibrutinib. Idelalisib The metabolism of Ibrutinib can be decreased when combined with Idelalisib. Ifosfamide The metabolism of Ibrutinib can be decreased when combined with Ifosfamide. Iloperidone The metabolism of Ibrutinib can be decreased when combined with Iloperidone. Iloprost The risk or severity of adverse effects can be increased when Ibrutinib is combined with Iloprost. Imatinib The metabolism of Ibrutinib can be decreased when combined with Imatinib. Imipramine The metabolism of Ibrutinib can be decreased when combined with Imipramine. Indinavir The metabolism of Ibrutinib can be decreased when combined with Indinavir. Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Ibrutinib. Inebilizumab The risk or severity of infection can be increased when Ibrutinib is combined with Inebilizumab. Infliximab The metabolism of Ibrutinib can be increased when combined with Infliximab. Irbesartan The metabolism of Ibrutinib can be decreased when combined with Irbesartan. Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Ibrutinib. Isavuconazole The metabolism of Ibrutinib can be decreased when combined with Isavuconazole. Isavuconazonium The metabolism of Ibrutinib can be decreased when combined with Isavuconazonium. Isoniazid The metabolism of Ibrutinib can be decreased when combined with Isoniazid. Isradipine The metabolism of Ibrutinib can be decreased when combined with Isradipine. Istradefylline The metabolism of Istradefylline can be decreased when combined with Ibrutinib. Itraconazole The metabolism of Ibrutinib can be decreased when combined with Itraconazole. Ivacaftor The metabolism of Ibrutinib can be decreased when combined with Ivacaftor. Ivosidenib The metabolism of Ibrutinib can be increased when combined with Ivosidenib. Ixabepilone The risk or severity of adverse effects can be increased when Ixabepilone is combined with Ibrutinib. Ixekizumab The risk or severity of adverse effects can be increased when Ibrutinib is combined with Ixekizumab. Janssen COVID The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Ibrutinib. Japanese The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Ibrutinib. Ketazolam The metabolism of Ibrutinib can be decreased when combined with Ketazolam. Ketoconazole The metabolism of Ibrutinib can be decreased when combined with Ketoconazole. Labetalol The metabolism of Ibrutinib can be decreased when combined with Labetalol. Lanreotide The metabolism of Ibrutinib can be decreased when combined with Lanreotide. Lansoprazole The metabolism of Ibrutinib can be decreased when combined with Lansoprazole. Lapatinib The metabolism of Ibrutinib can be decreased when combined with Lapatinib. Leflunomide The risk or severity of adverse effects can be increased when Ibrutinib is combined with Leflunomide. Lemborexant The metabolism of Lemborexant can be decreased when combined with Ibrutinib. Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Ibrutinib. Lepirudin The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Lepirudin. Lercanidipine The metabolism of Ibrutinib can be decreased when combined with Lercanidipine. Letermovir The metabolism of Ibrutinib can be decreased when combined with Letermovir. Levamlodipine The metabolism of Levamlodipine can be decreased when combined with Ibrutinib. Levobetaxolol The metabolism of Levobetaxolol can be decreased when combined with Ibrutinib. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Levobupivacaine. Levoketoconazole The metabolism of Ibrutinib can be decreased when combined with Levoketoconazole. Levomilnacipran The metabolism of Ibrutinib can be decreased when combined with Levomilnacipran. Levonorgestrel The metabolism of Ibrutinib can be decreased when combined with Levonorgestrel. Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Ibrutinib. Lidocaine The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Lidocaine. Linagliptin The metabolism of Ibrutinib can be decreased when combined with Linagliptin. Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Ibrutinib. Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Ibrutinib. Liotrix The therapeutic efficacy of Liotrix can be decreased when used in combination with Ibrutinib. Lipegfilgrastim Ibrutinib may increase the myelosuppressive activities of Lipegfilgrastim. Lisdexamfetamine The metabolism of Ibrutinib can be decreased when combined with Lisdexamfetamine. Lisuride The metabolism of Ibrutinib can be decreased when combined with Lisuride. Lofexidine The metabolism of Ibrutinib can be decreased when combined with Lofexidine. Lomitapide The metabolism of Ibrutinib can be decreased when combined with Lomitapide. Lomustine The risk or severity of adverse effects can be increased when Lomustine is combined with Ibrutinib. Lonafarnib The metabolism of Ibrutinib can be decreased when combined with Lonafarnib. Lopinavir The serum concentration of Ibrutinib can be increased when it is combined with Lopinavir. Lorcaserin The metabolism of Ibrutinib can be decreased when combined with Lorcaserin. Lorlatinib The metabolism of Lorlatinib can be decreased when combined with Ibrutinib. Lorpiprazole The metabolism of Lorpiprazole can be decreased when combined with Ibrutinib. Losartan The metabolism of Ibrutinib can be decreased when combined with Losartan. Lovastatin The metabolism of Ibrutinib can be decreased when combined with Lovastatin. Lumacaftor The metabolism of Ibrutinib can be increased when combined with Lumacaftor. Lumefantrine The metabolism of Ibrutinib can be decreased when combined with Lumefantrine. Magnesium The serum concentration of Magnesium can be decreased when it is combined with Ibrutinib. Manidipine The metabolism of Ibrutinib can be decreased when combined with Manidipine. Maprotiline The metabolism of Ibrutinib can be decreased when combined with Maprotiline. Mavacamten The serum concentration of Ibrutinib can be decreased when it is combined with Mavacamten. Measles virus The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Ibrutinib. Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Ibrutinib. Meclizine The metabolism of Ibrutinib can be decreased when combined with Meclizine. Mefloquine The metabolism of Ibrutinib can be decreased when combined with Mefloquine. Meloxicam The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Meloxicam. Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Ibrutinib. Meningococcal The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Ibrutinib. Mephenytoin The metabolism of Ibrutinib can be decreased when combined with Mephenytoin. Mepivacaine The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Mepivacaine. Mepolizumab The risk or severity of adverse effects can be increased when Mepolizumab is combined with Ibrutinib. Meprednisone The risk or severity of adverse effects can be increased when Ibrutinib is combined with Meprednisone. Mepyramine The metabolism of Ibrutinib can be decreased when combined with Mepyramine. Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Ibrutinib. Mesoridazine The metabolism of Ibrutinib can be decreased when combined with Mesoridazine. Metamfetamine The metabolism of Ibrutinib can be decreased when combined with Metamfetamine. Metamizole The risk or severity of myelosuppression can be increased when Metamizole is combined with Ibrutinib. Methadone The metabolism of Ibrutinib can be decreased when combined with Methadone. Methimazole The metabolism of Ibrutinib can be decreased when combined with Methimazole. Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Ibrutinib. Methotrimeprazine The metabolism of Ibrutinib can be decreased when combined with Methotrimeprazine. Methylene blue The metabolism of Ibrutinib can be decreased when combined with Methylene blue. Methylergometrine The metabolism of Ibrutinib can be decreased when combined with Methylergometrine. Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ibrutinib. Metoclopramide The metabolism of Ibrutinib can be decreased when combined with Metoclopramide. Metoprolol The metabolism of Ibrutinib can be decreased when combined with Metoprolol. Metreleptin The metabolism of Ibrutinib can be increased when combined with Metreleptin. Metronidazole The metabolism of Ibrutinib can be decreased when combined with Metronidazole. Metyrapone The metabolism of Ibrutinib can be decreased when combined with Metyrapone. Mexiletine The metabolism of Ibrutinib can be decreased when combined with Mexiletine. Mianserin The metabolism of Ibrutinib can be decreased when combined with Mianserin. Miconazole The metabolism of Ibrutinib can be decreased when combined with Miconazole. Midazolam The metabolism of Ibrutinib can be decreased when combined with Midazolam. Midostaurin The metabolism of Ibrutinib can be decreased when combined with Midostaurin. Mifepristone The metabolism of Ibrutinib can be decreased when combined with Mifepristone. Milnacipran The metabolism of Ibrutinib can be decreased when combined with Milnacipran. Minaprine The metabolism of Ibrutinib can be decreased when combined with Minaprine. Mirabegron The serum concentration of Ibrutinib can be increased when it is combined with Mirabegron. Mirtazapine The metabolism of Ibrutinib can be decreased when combined with Mirtazapine. Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Ibrutinib. Mitotane The metabolism of Ibrutinib can be increased when combined with Mitotane. Mitoxantrone The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Ibrutinib. Mobocertinib The metabolism of Mobocertinib can be decreased when combined with Ibrutinib. Moclobemide The metabolism of Ibrutinib can be decreased when combined with Moclobemide. Modafinil The metabolism of Ibrutinib can be increased when combined with Modafinil. Moderna COVID The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Ibrutinib. Modified vaccinia The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Ibrutinib. Mometasone fur The risk or severity of adverse effects can be increased when Ibrutinib is combined with Mometasone furoate. Monomethyl fum The risk or severity of adverse effects can be increased when Ibrutinib is combined with Monomethyl fumarate. Mosunetuzumab The risk or severity of adverse effects can be increased when Ibrutinib is combined with Mosunetuzumab. Mumps virus The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Ibrutinib. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Ibrutinib. Mycophenolate The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ibrutinib. Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ibrutinib. Nadolol The metabolism of Ibrutinib can be decreased when combined with Nadolol. Nadroparin The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Nadroparin. Naloxone The metabolism of Ibrutinib can be decreased when combined with Naloxone. Natalizumab The risk or severity of adverse effects can be increased when Ibrutinib is combined with Natalizumab. Nateglinide The metabolism of Ibrutinib can be decreased when combined with Nateglinide. Nebivolol The metabolism of Ibrutinib can be decreased when combined with Nebivolol. Nefazodone The metabolism of Ibrutinib can be decreased when combined with Nefazodone. Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Ibrutinib. Nelfinavir The metabolism of Ibrutinib can be decreased when combined with Nelfinavir. Netupitant The metabolism of Ibrutinib can be decreased when combined with Netupitant. Nevirapine The metabolism of Ibrutinib can be decreased when combined with Nevirapine. Niacin The metabolism of Ibrutinib can be decreased when combined with Niacin. Nicardipine The metabolism of Ibrutinib can be decreased when combined with Nicardipine. Nicergoline The metabolism of Ibrutinib can be decreased when combined with Nicergoline. Nifedipine The metabolism of Ibrutinib can be decreased when combined with Nifedipine. Nilotinib The metabolism of Ibrutinib can be decreased when combined with Nilotinib. Nilvadipine The metabolism of Ibrutinib can be decreased when combined with Nilvadipine. Nimesulide The risk or severity of adverse effects can be increased when Ibrutinib is combined with Nimesulide. Nisoldipine The metabolism of Ibrutinib can be decreased when combined with Nisoldipine. Nitrendipine The metabolism of Ibrutinib can be decreased when combined with Nitrendipine. Nitric Oxide The metabolism of Ibrutinib can be decreased when combined with Nitric Oxide. Norethisterone The metabolism of Ibrutinib can be decreased when combined with Norethisterone. Norfloxacin The metabolism of Ibrutinib can be decreased when combined with Norfloxacin. Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Ibrutinib. Noscapine The metabolism of Ibrutinib can be decreased when combined with Noscapine. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Ibrutinib. Obinutuzumab The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Ibrutinib. Ocrelizumab The risk or severity of adverse effects can be increased when Ibrutinib is combined with Ocrelizumab. Octreotide The metabolism of Ibrutinib can be decreased when combined with Octreotide. Ofatumumab The risk or severity of adverse effects can be increased when Ofatumumab is combined with Ibrutinib. Olanzapine The metabolism of Ibrutinib can be decreased when combined with Olanzapine. Olaparib The metabolism of Ibrutinib can be decreased when combined with Olaparib. Oliceridine The metabolism of Oliceridine can be decreased when combined with Ibrutinib. Olutasidenib The therapeutic efficacy of Ibrutinib can be decreased when used in combination with Olutasidenib. Omega-3 fatty acids Omega-3 fatty acids may increase the antiplatelet activities of Ibrutinib. Omega-3-a Omega-3-acid ethyl esters may increase the antiplatelet activities of Ibrutinib. Omega-3- Omega-3-carboxylic acids may increase the antiplatelet activities of Ibrutinib. Omeprazole The metabolism of Ibrutinib can be decreased when combined with Omeprazole. Ondansetron The metabolism of Ibrutinib can be decreased when combined with Ondansetron. Opium The metabolism of Opium can be decreased when combined with Ibrutinib. Oritavancin The metabolism of Ibrutinib can be decreased when combined with Oritavancin. Orphenadrine The metabolism of Ibrutinib can be decreased when combined with Orphenadrine. Osilodrostat The metabolism of Ibrutinib can be decreased when combined with Osilodrostat. Ospemifene The metabolism of Ibrutinib can be decreased when combined with Ospemifene. Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ibrutinib. Oxamniquine The metabolism of Ibrutinib can be decreased when combined with Oxamniquine. Oxcarbazepine The metabolism of Ibrutinib can be decreased when combined with Oxcarbazepine. Oxetacaine The metabolism of Ibrutinib can be decreased when combined with Oxetacaine. Oxprenolol The metabolism of Ibrutinib can be decreased when combined with Oxprenolol. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Oxybuprocaine. Oxybutynin The metabolism of Ibrutinib can be decreased when combined with Oxybutynin. Oxycodone The metabolism of Ibrutinib can be decreased when combined with Oxycodone. Oxymetholone The metabolism of Ibrutinib can be decreased when combined with Oxymetholone. Oxymorphone The metabolism of Ibrutinib can be decreased when combined with Oxymorphone. Ozanimod The risk or severity of adverse effects can be increased when Ibrutinib is combined with Ozanimod. Paclitaxel The metabolism of Paclitaxel can be decreased when combined with Ibrutinib. Palbociclib The metabolism of Ibrutinib can be decreased when combined with Palbociclib. Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Ibrutinib. Paliperidone The metabolism of Ibrutinib can be decreased when combined with Paliperidone. Palonosetron The metabolism of Ibrutinib can be decreased when combined with Palonosetron. Panobinostat The metabolism of Ibrutinib can be decreased when combined with Panobinostat. Parathyroid The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Ibrutinib. Paritaprevir The metabolism of Paritaprevir can be decreased when combined with Ibrutinib. Parnaparin The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Parnaparin. Paroxetine The metabolism of Ibrutinib can be decreased when combined with Paroxetine. Pasireotide The metabolism of Ibrutinib can be decreased when combined with Pasireotide. Pazopanib The metabolism of Ibrutinib can be decreased when combined with Pazopanib. pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ibrutinib. Pegcetacoplan The risk or severity of adverse effects can be increased when Ibrutinib is combined with Pegcetacoplan. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Ibrutinib. Peginterferon The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ibrutinib. Peginterferon alf The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ibrutinib. Peginterferon beta The risk or severity of adverse effects can be increased when Ibrutinib is combined with Peginterferon beta-1a. Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Ibrutinib. Penbutolol The metabolism of Ibrutinib can be decreased when combined with Penbutolol. Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Ibrutinib. Pentamidine The metabolism of Ibrutinib can be decreased when combined with Pentamidine. Pentobarbital The metabolism of Ibrutinib can be increased when combined with Pentobarbital. Pentosan The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Pentosan polysulfate. Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Ibrutinib. Pentoxifylline The risk or severity of adverse effects can be increased when Ibrutinib is combined with Pentoxifylline. Peppermint oil The metabolism of Ibrutinib can be decreased when combined with Peppermint oil. Perampanel The metabolism of Ibrutinib can be decreased when combined with Perampanel. Perhexiline The metabolism of Ibrutinib can be decreased when combined with Perhexiline. Perphenazine The metabolism of Ibrutinib can be decreased when combined with Perphenazine. Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Ibrutinib. Phenelzine The metabolism of Ibrutinib can be decreased when combined with Phenelzine. Phenformin The metabolism of Ibrutinib can be decreased when combined with Phenformin. Phenindione The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Phenindione. Phenobarbital The metabolism of Ibrutinib can be increased when combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Phenol. Phenprocoumon The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Phenprocoumon. Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Ibrutinib. Phenylbutyric acid The metabolism of Ibrutinib can be decreased when combined with Phenylbutyric acid. Phenytoin The metabolism of Ibrutinib can be increased when combined with Phenytoin. Pilocarpine The metabolism of Ibrutinib can be decreased when combined with Pilocarpine. Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibrutinib. Pimozide The metabolism of Ibrutinib can be decreased when combined with Pimozide. Pindolol The metabolism of Ibrutinib can be decreased when combined with Pindolol. Piperaquine The metabolism of Ibrutinib can be decreased when combined with Piperaquine. Piperazine The metabolism of Ibrutinib can be decreased when combined with Piperazine. Pipotiazine The metabolism of Ibrutinib can be decreased when combined with Pipotiazine. Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Ibrutinib. Pitolisant The serum concentration of Ibrutinib can be decreased when it is combined with Pitolisant. Polythiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Ibrutinib. Pomalidomide The risk or severity of adverse effects can be increased when Pomalidomide is combined with Ibrutinib. Ponatinib The metabolism of Ponatinib can be decreased when combined with Ibrutinib. Ponesimod The risk or severity of adverse effects can be increased when Ibrutinib is combined with Ponesimod. Posaconazole The metabolism of Ibrutinib can be decreased when combined with Posaconazole. Potassium Iodide The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Ibrutinib. Potassium The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Ibrutinib. Practolol The metabolism of Ibrutinib can be decreased when combined with Practolol. Pralatrexate The risk or severity of adverse effects can be increased when Pralatrexate is combined with Ibrutinib. Pralsetinib The metabolism of Ibrutinib can be decreased when combined with Pralsetinib. Pramocaine The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Pramocaine. Prasugrel The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Prasugrel. Praziquantel The metabolism of Ibrutinib can be decreased when combined with Praziquantel. Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Ibrutinib. Prednisolone The metabolism of Ibrutinib can be increased when combined with Prednisolone phosphate. Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Ibrutinib. Prednisone acetate The metabolism of Ibrutinib can be increased when combined with Prednisone acetate. Prilocaine The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Prilocaine. Primaquine The metabolism of Ibrutinib can be decreased when combined with Primaquine. Primidone The metabolism of Ibrutinib can be increased when combined with Primidone. Procainamide The metabolism of Procainamide can be decreased when combined with Ibrutinib. Procaine The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Procaine. Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Ibrutinib. Prochlorperazine The metabolism of Ibrutinib can be decreased when combined with Prochlorperazine. Progesterone The metabolism of Ibrutinib can be decreased when combined with Progesterone. Proguanil The metabolism of Ibrutinib can be decreased when combined with Proguanil. Promazine The metabolism of Ibrutinib can be decreased when combined with Promazine. Promethazine The metabolism of Ibrutinib can be decreased when combined with Promethazine. Propafenone The metabolism of Ibrutinib can be decreased when combined with Propafenone. Proparacaine The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Proparacaine. Propofol The metabolism of Ibrutinib can be decreased when combined with Propofol. Propoxycaine The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Propoxycaine. Propranolol The metabolism of Ibrutinib can be decreased when combined with Propranolol. Propylthiouracil The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Ibrutinib. Protein C The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Protein C. Protein S The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Protein S human. Protirelin The therapeutic efficacy of Protirelin can be decreased when used in combination with Ibrutinib. Quetiapine The metabolism of Ibrutinib can be decreased when combined with Quetiapine. Quinidine The metabolism of Ibrutinib can be decreased when combined with Quinidine. Quinine The metabolism of Ibrutinib can be decreased when combined with Quinine. Quinupristin The metabolism of Ibrutinib can be decreased when combined with Quinupristin. Rabeprazole The metabolism of Ibrutinib can be decreased when combined with Rabeprazole. Rabies immun The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Ibrutinib. Rabies virus The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ibrutinib. Rabies virus The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Ibrutinib. Raloxifene The metabolism of Ibrutinib can be decreased when combined with Raloxifene. Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Ibrutinib. Ranitidine The metabolism of Ibrutinib can be decreased when combined with Ranitidine. Ranolazine The metabolism of Ibrutinib can be decreased when combined with Ranolazine. Ravulizumab The risk or severity of adverse effects can be increased when Ibrutinib is combined with Ravulizumab. Reboxetine The metabolism of Ibrutinib can be decreased when combined with Reboxetine. Regorafenib The metabolism of Ibrutinib can be decreased when combined with Regorafenib. Relugolix The metabolism of Relugolix can be decreased when combined with Ibrutinib. Remdesivir The metabolism of Ibrutinib can be decreased when combined with Remdesivir. Remoxipride The metabolism of Ibrutinib can be decreased when combined with Remoxipride. Reserpine The metabolism of Ibrutinib can be increased when combined with Reserpine. Reteplase The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Reteplase. Revefenacin The metabolism of Revefenacin can be decreased when combined with Ibrutinib. Reviparin The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Reviparin. Ribociclib The metabolism of Ibrutinib can be decreased when combined with Ribociclib. Rifampicin The metabolism of Ibrutinib can be increased when combined with Rifampicin. Rifamycin The metabolism of Ibrutinib can be decreased when combined with Rifamycin. Rifapentine The metabolism of Ibrutinib can be increased when combined with Rifapentine. Rilonacept The metabolism of Ibrutinib can be increased when combined with Rilonacept. Rilpivirine The metabolism of Ibrutinib can be decreased when combined with Rilpivirine. Risankizumab The risk or severity of adverse effects can be increased when Ibrutinib is combined with Risankizumab. Risperidone The metabolism of Ibrutinib can be decreased when combined with Risperidone. Ritonavir The serum concentration of Ibrutinib can be increased when it is combined with Ritonavir. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Ibrutinib. Rivaroxaban The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Rivaroxaban. Roflumilast Roflumilast may increase the immunosuppressive activities of Ibrutinib. Rolapitant The metabolism of Ibrutinib can be decreased when combined with Rolapitant. Romidepsin The metabolism of Ibrutinib can be decreased when combined with Romidepsin. Ropeginterferon The risk or severity of adverse effects can be increased when Ibrutinib is combined with Ropeginterferon alfa-2b. Ropivacaine The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Ropivacaine. Rosuvastatin The metabolism of Ibrutinib can be decreased when combined with Rosuvastatin. Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Ibrutinib. Rotigotine The metabolism of Ibrutinib can be decreased when combined with Rotigotine. Roxithromycin The metabolism of Ibrutinib can be decreased when combined with Roxithromycin. Rubella viru The risk or severity of infection can be increased when Rubella virus vaccine is combined with Ibrutinib. Rucaparib The metabolism of Ibrutinib can be decreased when combined with Rucaparib. Rupatadine The metabolism of Rupatadine can be decreased when combined with Ibrutinib. Rutin The metabolism of Ibrutinib can be decreased when combined with Rutin. Ruxolitinib The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ibrutinib. Salmeterol The metabolism of Ibrutinib can be decreased when combined with Salmeterol. Salmon calcitonin The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Ibrutinib. Saquinavir The metabolism of Ibrutinib can be decreased when combined with Saquinavir. Sarilumab The metabolism of Ibrutinib can be decreased when combined with Sarilumab. Satralizumab The serum concentration of Ibrutinib can be decreased when it is combined with Satralizumab. Saxagliptin The metabolism of Ibrutinib can be decreased when combined with Saxagliptin. Secukinumab The metabolism of Ibrutinib can be increased when combined with Secukinumab. Selegiline The metabolism of Ibrutinib can be decreased when combined with Selegiline. Selumetinib The metabolism of Selumetinib can be decreased when combined with Ibrutinib. Sertindole The metabolism of Ibrutinib can be decreased when combined with Sertindole. Sertraline The metabolism of Ibrutinib can be decreased when combined with Sertraline. Sildenafil The metabolism of Ibrutinib can be decreased when combined with Sildenafil. Siltuximab The metabolism of Ibrutinib can be decreased when combined with Siltuximab. Simeprevir The metabolism of Ibrutinib can be decreased when combined with Simeprevir. Simvastatin The metabolism of Ibrutinib can be decreased when combined with Simvastatin. Siponimod The risk or severity of adverse effects can be increased when Ibrutinib is combined with Siponimod. Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ibrutinib. Sirolimus The metabolism of Sirolimus can be decreased when combined with Ibrutinib. Sitaxentan The metabolism of Ibrutinib can be decreased when combined with Sitaxentan. Smallpox The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Ibrutinib. Sodium citrate The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Sodium citrate. Solifenacin The metabolism of Ibrutinib can be decreased when combined with Solifenacin. Somatostatin The metabolism of Ibrutinib can be decreased when combined with Somatostatin. Somatrogon The metabolism of Ibrutinib can be increased when combined with Somatrogon. Sorafenib The metabolism of Ibrutinib can be decreased when combined with Sorafenib. Sotalol The metabolism of Sotalol can be decreased when combined with Ibrutinib. Sotorasib The serum concentration of Ibrutinib can be decreased when it is combined with Sotorasib. Spesolimab The risk or severity of adverse effects can be increased when Ibrutinib is combined with Spesolimab. St. John's Wort The metabolism of Ibrutinib can be increased when combined with St. John's Wort. Stiripentol The metabolism of Ibrutinib can be decreased when combined with Stiripentol. Streptokinase The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Streptokinase. Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Ibrutinib. Sulfamethoxazole The metabolism of Ibrutinib can be decreased when combined with Sulfamethoxazole. Sulfaphenazole The metabolism of Ibrutinib can be decreased when combined with Sulfaphenazole. Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ibrutinib. Sulfinpyrazone The risk or severity of adverse effects can be increased when Ibrutinib is combined with Sulfinpyrazone. Sulodexide The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Sulodexide. Sunitinib The metabolism of Ibrutinib can be decreased when combined with Sunitinib. Tacrolimus The metabolism of Ibrutinib can be decreased when combined with Tacrolimus. Tadalafil The metabolism of Ibrutinib can be decreased when combined with Tadalafil. Tafenoquine The metabolism of Ibrutinib can be decreased when combined with Tafenoquine. Tamoxifen The metabolism of Ibrutinib can be decreased when combined with Tamoxifen. Tamsulosin The metabolism of Ibrutinib can be decreased when combined with Tamsulosin. Tedizolid The risk or severity of myelosuppression can be increased when Tedizolid phosphate is combined with Ibrutinib. Tegafur The metabolism of Tegafur can be decreased when combined with Ibrutinib. Tegaserod The metabolism of Ibrutinib can be decreased when combined with Tegaserod. Telaprevir The metabolism of Ibrutinib can be decreased when combined with Telaprevir. Telithromycin The metabolism of Ibrutinib can be decreased when combined with Telithromycin. Telotristat ethyl The serum concentration of Ibrutinib can be decreased when it is combined with Telotristat ethyl. Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Ibrutinib. Temsirolimus The metabolism of Temsirolimus can be decreased when combined with Ibrutinib. Tenecteplase The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Tenecteplase. Teniposide The metabolism of Ibrutinib can be decreased when combined with Teniposide. Teprotumumab The risk or severity of adverse effects can be increased when Teprotumumab is combined with Ibrutinib. Terbinafine The metabolism of Ibrutinib can be decreased when combined with Terbinafine. Terfenadine The metabolism of Ibrutinib can be decreased when combined with Terfenadine. Teriflunomide The risk or severity of adverse effects can be increased when Teriflunomide is combined with Ibrutinib. Teriparatide The therapeutic efficacy of Teriparatide can be decreased when used in combination with Ibrutinib. Testosterone The metabolism of Ibrutinib can be decreased when combined with Testosterone. Testosterone The metabolism of Ibrutinib can be decreased when combined with Testosterone cypionate. Testosterone en The metabolism of Ibrutinib can be decreased when combined with Testosterone enanthate. Testosterone un The metabolism of Ibrutinib can be decreased when combined with Testosterone undecanoate. Tetrabenazine The metabolism of Ibrutinib can be decreased when combined with Tetrabenazine. Tetracaine The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Tetracaine. Tetracycline The metabolism of Ibrutinib can be decreased when combined with Tetracycline. Tezacaftor The metabolism of Tezacaftor can be decreased when combined with Ibrutinib. Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Ibrutinib. Theophylline The metabolism of Theophylline can be decreased when combined with Ibrutinib. Thiopental The metabolism of Ibrutinib can be decreased when combined with Thiopental. Thioridazine The metabolism of Ibrutinib can be decreased when combined with Thioridazine. Thiotepa The risk or severity of adverse effects can be increased when Thiotepa is combined with Ibrutinib. Thyroid, porcine The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Ibrutinib. Thyrotropin alfa The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Ibrutinib. Ticagrelor The metabolism of Ibrutinib can be decreased when combined with Ticagrelor. Tick-borne The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Ibrutinib. Ticlopidine The risk or severity of adverse effects can be increased when Ibrutinib is combined with Ticlopidine. Timolol The metabolism of Ibrutinib can be decreased when combined with Timolol. Tinzaparin The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Tinzaparin. Tioconazole The metabolism of Ibrutinib can be decreased when combined with Tioconazole. Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Ibrutinib. Tiotropium The metabolism of Ibrutinib can be decreased when combined with Tiotropium. Tipranavir The metabolism of Ibrutinib can be decreased when combined with Tipranavir. Tirofiban The risk or severity of adverse effects can be increased when Ibrutinib is combined with Tirofiban. Tixocortol The risk or severity of adverse effects can be increased when Ibrutinib is combined with Tixocortol. Tocilizumab The metabolism of Ibrutinib can be increased when combined with Tocilizumab. Tofacitinib Ibrutinib may increase the immunosuppressive activities of Tofacitinib. Tolterodine The metabolism of Ibrutinib can be decreased when combined with Tolterodine. Topotecan The metabolism of Ibrutinib can be decreased when combined with Topotecan. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Ibrutinib. Trabectedin The metabolism of Trabectedin can be decreased when combined with Ibrutinib. Tramadol The metabolism of Ibrutinib can be decreased when combined with Tramadol. Tranylcypromine The metabolism of Ibrutinib can be decreased when combined with Tranylcypromine. Trastuzumab Trastuzumab may increase the neutropenic activities of Ibrutinib. Trastuzumab The metabolism of Trastuzumab emtansine can be decreased when combined with Ibrutinib. Trazodone The metabolism of Ibrutinib can be decreased when combined with Trazodone. Tretinoin The risk or severity of adverse effects can be increased when Tretinoin is combined with Ibrutinib. Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Ibrutinib. Triazolam The metabolism of Ibrutinib can be decreased when combined with Triazolam. Trichlormethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Ibrutinib. Triclabendazole The metabolism of Ibrutinib can be decreased when combined with Triclabendazole. Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Ibrutinib. Triflusal The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Triflusal. Trilostane The risk or severity of adverse effects can be increased when Trilostane is combined with Ibrutinib. Trimipramine The metabolism of Trimipramine can be decreased when combined with Ibrutinib. Tripelennamine The metabolism of Ibrutinib can be decreased when combined with Tripelennamine. Troglitazone The metabolism of Ibrutinib can be decreased when combined with Troglitazone. Troleandomycin The metabolism of Ibrutinib can be decreased when combined with Troleandomycin. Trospium The metabolism of Ibrutinib can be decreased when combined with Trospium. Tucatinib The metabolism of Tucatinib can be decreased when combined with Ibrutinib. Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Ibrutinib. Typhoid Vaccine The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Ibrutinib. Typhoid Vi The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Ibrutinib. Udenafil The metabolism of Ibrutinib can be decreased when combined with Udenafil. Umeclidinium The metabolism of Umeclidinium can be decreased when combined with Ibrutinib. Upadacitinib The risk or severity of adverse effects can be increased when Ibrutinib is combined with Upadacitinib. Urokinase The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Urokinase. Valentine The metabolism of Valbenazine can be decreased when combined with Ibrutinib. Valproic acid The metabolism of Ibrutinib can be decreased when combined with Valproic acid. Vardenafil The metabolism of Ibrutinib can be decreased when combined with Vardenafil. Varicella zoster The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Ibrutinib. Varicella zoster The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Ibrutinib. Vedolizumab The risk or severity of adverse effects can be increased when Vedolizumab is combined with Ibrutinib. Vemurafenib The metabolism of Ibrutinib can be decreased when combined with Vemurafenib. Venetoclax The metabolism of Ibrutinib can be decreased when combined with Venetoclax. Venlafaxine The metabolism of Ibrutinib can be decreased when combined with Venlafaxine. Verapamil The metabolism of Ibrutinib can be decreased when combined with Verapamil. Vernakalant The metabolism of Ibrutinib can be decreased when combined with Vernakalant. Vibrio cholerae The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Ibrutinib. Vilanterol The risk or severity of adverse effects can be increased when Ibrutinib is combined with Vilanterol. Vilazodone The metabolism of Ibrutinib can be decreased when combined with Vilazodone. Viloxazine The metabolism of Ibrutinib can be decreased when combined with Viloxazine. Vinblastine The metabolism of Ibrutinib can be decreased when combined with Vinblastine. Vincristine The metabolism of Vincristine can be decreased when combined with Ibrutinib. Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Ibrutinib. Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Ibrutinib. Vitamin E Vitamin E may increase the antiplatelet activities of Ibrutinib. Voclosporin The risk or severity of adverse effects can be increased when Ibrutinib is combined with Voclosporin. Vonoprazan The metabolism of Vonoprazan can be decreased when combined with Ibrutinib. Vorapaxar The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Vorapaxar. Voriconazole The metabolism of Ibrutinib can be decreased when combined with Voriconazole. Vorinostat The risk or severity of adverse effects can be increased when Vorinostat is combined with Ibrutinib. Vortioxetine The metabolism of Vortioxetine can be decreased when combined with Ibrutinib. Warfarin The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Warfarin. Ximelagatran The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Ximelagatran. Yellow fever The risk or severity of infection can be increased when Yellow fever vaccine is combined with Ibrutinib. Yohimbine The metabolism of Ibrutinib can be decreased when combined with Yohimbine. Zafirlukast The metabolism of Ibrutinib can be decreased when combined with Zafirlukast. Zaleplon The metabolism of Ibrutinib can be decreased when combined with Zaleplon. Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Ibrutinib. Zimelidine The metabolism of Ibrutinib can be decreased when combined with Zimelidine. Ziprasidone The metabolism of Ibrutinib can be decreased when combined with Ziprasidone. Zolpidem The metabolism of Ibrutinib can be decreased when combined with Zolpidem. Zonisamide The metabolism of Ibrutinib can be decreased when combined with Zonisamide. Zuclopenthixol The metabolism of Ibrutinib can be decreased when combined with Zuclopenthixol Pregnancy and Lactation AU TGA pregnancy category: D US FDA pregnancy category: Not Assigned Pregnancy This drug is a kinase inhibitor and can cause fetal harm based on findings from animal studies. Administration to pregnant animals during organogenesis at exposures up to 2 to 20 times the recommended human dose caused embryofetal toxicity including structural abnormalities. This drug should not be used during pregnancy unless the benefit outweighs the risk to the fetus. Advise females of reproductive potential and male patients to use effective contraceptive measures during therapy and for 1 to 3 months after. Females taking hormonal contraception should add a barrier contraceptive method as it is currently unknown whether this drug reduces the effectiveness of hormonal contraceptives. Male patients should not donate sperm during therapy and for 1 to 3 months after. Verify the pregnancy status of females of reproductive potential prior to initiating therapy. The time following treatment with this drug when it is safe to become pregnant is unknown. Lactation No information is available on the clinical use of ibrutinib during breastfeeding. Because ibrutinib is more than 97% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during ibrutinib therapy and for 1 week after the last dose. How should this medicine be used?

Ibrutinib comes as a capsule and a tablet to take by mouth. It is usually taken once daily. Take ibrutinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take ibrutinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Swallow the capsules whole with a glass of water; do…

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area from the RX Article Professional Blocks panel.

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   Vasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    Cholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    Imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    A thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    Propylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    Methimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    Mirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)